Preliminary Injunction Against Apotex Upheld on Appeal

    PARIS and NEW YORK, Dec. 8 /PRNewswire-FirstCall/ -- Sanofi-aventis
 (Paris Bourse: EURONEXT: SAN; and New York: NYSE:   SNY) and Bristol-Myers
 Squibb Company (New York: NYSE:   BMY) (the "companies") announced today that
 the United States Court of Appeals for the Federal Circuit has upheld the
 August 31, 2006 preliminary injunction issued by the United States District
 Court for the Southern District of New York. The injunction ordered Apotex
 to halt its sales of a generic version of clopidogrel bisulfate that
 competes with PLAVIX(R) pending the District Court's decision in the trial
 on the merits. As a result of the decision of the Court of Appeals, the
 preliminary injunction remains in place.
     The companies believe that the Apotex generic product infringes their
 intellectual property rights, which they continue to vigorously defend in
 the pending patent litigation. Trial on the merits is currently scheduled
 to begin on January 22, 2007.
     About sanofi-aventis
     Sanofi-aventis is the world's third largest pharmaceutical company,
 ranking number one in Europe. Backed by a world-class R&D organization,
 sanofi-aventis is developing leading positions in seven major therapeutic
 areas: cardiovascular, thrombosis, oncology, metabolic diseases, central
 nervous system, internal medicine, and vaccines.
     About Bristol-Myers Squibb
     Bristol-Myers Squibb is a global pharmaceutical and related health care
 products company whose mission is to extend and enhance human life.
     Statements on Cautionary Factors
     Sanofi-aventis
     This press release contains forward-looking statements as defined in
 the Private Securities Litigation Reform Act of 1995, as amended.
 Forward-looking statements are statements that are not historical facts.
 These statements include financial projections and estimates and their
 underlying assumptions, statements regarding plans, objectives, intentions
 and expectations with respect to future events, operations, products and
 services, and statements regarding future performance. Forward-looking
 statements are generally identified by the words "expect," "anticipates,"
 "believes," "intends," "estimates," "plans" and similar expressions.
 Although sanofi-aventis' management believes that the expectations
 reflected in such forward-looking statements are reasonable, investors are
 cautioned that forward-looking information and statements are subject to
 various risks and uncertainties, many of which are difficult to predict and
 generally beyond the control of sanofi-aventis, that could cause actual
 results and developments to differ materially from those expressed in, or
 implied or projected by, the forward- looking information and statements.
 These risks and uncertainties include risks that may arise from the
 Department of Justice's criminal investigation on the Plavix(R) proposed
 settlement with Apotex, the adverse impact of Apotex's launch and generic
 product distributed into the market prior to the Court's injunction, the
 potential launch of a generic clopidogrel bisulfate product by other
 entities, as well as those discussed or identified in the public filings
 with the SEC and the AMF made by sanofi-aventis, including those listed
 under "Risk Factors" and "Cautionary Statement Regarding Forward- Looking
 Statements" in sanofi-aventis' annual report on Form 20-F for the year
 ended December 31, 2005. Other than as required by applicable law, sanofi-
 aventis does not undertake any obligation to update or revise any forward-
 looking information or statements.
     Bristol-Myers Squibb
     This press release contains certain forward-looking statements within
 the meaning of the Private Securities Litigation Reform Act of 1995
 regarding, among other things, statements relating to goals, plans and
 projections regarding the company's financial position. These statements
 may be identified by the fact that they use words such as "anticipate,"
 "estimates," "expect," "guidance," "project," "intend," "plan," "believe"
 and other words and terms of similar meaning in connection with any
 discussion of future operating or financial performance. Such
 forward-looking statements are based on current expectations and involve
 inherent risks and uncertainties, including factors that could delay,
 divert or change any of them, and could cause actual outcomes and results
 to differ materially from current expectations. These risks and
 uncertainties include the inherent unpredictability of matters in
 litigation, the risks that may arise from the Department of Justice's
 criminal investigation on the Plavix(R) proposed settlement with Apotex,
 the adverse impact of Apotex's launch and generic product distributed into
 the market prior to the Court's injunction and the potential launch of a
 generic clopidogrel bisulfate product by other generic pharmaceutical
 companies. For further details and a discussion of these and other risks
 and uncertainties, see the company's periodic reports, including current
 reports on Form 8-K, quarterly reports on Form 10-Q and the annual report
 on Form 10-K, furnished to and filed with the Securities and Exchange
 Commission. The company undertakes no obligation to publicly update any
 forward-looking statement, whether as a result of new information, future
 events or otherwise.
 
 

SOURCE Bristol-Myers Squibb; sanofi-aventis
RELATED LINKS
http://www.bms.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.